Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
3703 | 1848 | 32.6 | 70% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
276 | 18466 | BREAST CANCER//ACCELERATED PARTIAL BREAST IRRADIATION//PARTIAL BREAST IRRADIATION |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | METASTATIC BREAST CANCER | Author keyword | 162 | 31% | 24% | 439 |
2 | VINORELBINE | Author keyword | 40 | 20% | 10% | 183 |
3 | DOCETAXEL | Author keyword | 35 | 10% | 18% | 327 |
4 | CAPECITABINE | Author keyword | 28 | 14% | 10% | 190 |
5 | ADVANCED BREAST CANCER | Author keyword | 17 | 19% | 4% | 81 |
6 | ANTHRACYCLINE RESISTANT | Author keyword | 15 | 88% | 0% | 7 |
7 | NO ALBERTA BREAST CANC PROGRAM | Address | 14 | 100% | 0% | 7 |
8 | ANTHRACYCLINE RESISTANCE | Author keyword | 12 | 50% | 1% | 17 |
9 | DOCETAXEL TAXOTERER | Author keyword | 10 | 73% | 0% | 8 |
10 | CANC THER Y DEV PROGRAM | Address | 6 | 80% | 0% | 4 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | METASTATIC BREAST CANCER | 162 | 31% | 24% | 439 | Search METASTATIC+BREAST+CANCER | Search METASTATIC+BREAST+CANCER |
2 | VINORELBINE | 40 | 20% | 10% | 183 | Search VINORELBINE | Search VINORELBINE |
3 | DOCETAXEL | 35 | 10% | 18% | 327 | Search DOCETAXEL | Search DOCETAXEL |
4 | CAPECITABINE | 28 | 14% | 10% | 190 | Search CAPECITABINE | Search CAPECITABINE |
5 | ADVANCED BREAST CANCER | 17 | 19% | 4% | 81 | Search ADVANCED+BREAST+CANCER | Search ADVANCED+BREAST+CANCER |
6 | ANTHRACYCLINE RESISTANT | 15 | 88% | 0% | 7 | Search ANTHRACYCLINE+RESISTANT | Search ANTHRACYCLINE+RESISTANT |
7 | ANTHRACYCLINE RESISTANCE | 12 | 50% | 1% | 17 | Search ANTHRACYCLINE+RESISTANCE | Search ANTHRACYCLINE+RESISTANCE |
8 | DOCETAXEL TAXOTERER | 10 | 73% | 0% | 8 | Search DOCETAXEL+TAXOTERER | Search DOCETAXEL+TAXOTERER |
9 | ORAL VINORELBINE | 5 | 33% | 1% | 13 | Search ORAL+VINORELBINE | Search ORAL+VINORELBINE |
10 | ADVANCED BREAST CARCINOMA | 5 | 55% | 0% | 6 | Search ADVANCED+BREAST+CARCINOMA | Search ADVANCED+BREAST+CARCINOMA |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CLINICAL SCREENING GROUP | 103 | 97% | 2% | 30 |
2 | WEEKLY IV VINORELBINE | 88 | 89% | 2% | 40 |
3 | INTRAVENOUS VINORELBINE | 82 | 70% | 4% | 68 |
4 | ANTHRACYCLINE RESISTANT | 74 | 54% | 5% | 94 |
5 | ANTHRACYCLINE PRETREATED PATIENTS | 53 | 85% | 2% | 28 |
6 | FIRST LINE CHEMOTHERAPY | 51 | 50% | 4% | 74 |
7 | FIRST LINE | 46 | 59% | 3% | 51 |
8 | LINE CHEMOTHERAPY | 34 | 65% | 2% | 32 |
9 | 3 HOUR INFUSION | 32 | 32% | 4% | 81 |
10 | 1ST LINE CHEMOTHERAPY | 29 | 20% | 7% | 130 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Docetaxel - A review of its use in metastatic breast cancer | 2005 | 81 | 55 | 78% |
Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy | 2006 | 45 | 106 | 77% |
Treatment of metastatic breast cancer: second line and beyond | 2011 | 24 | 51 | 53% |
Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer | 2011 | 16 | 166 | 72% |
Chemotherapy of metastatic breast cancer: What to expect in 2001 and beyond | 2001 | 106 | 73 | 74% |
Capecitabine Monotherapy: Review of Studies in First-Line HER-2-Negative Metastatic Breast Cancer | 2012 | 13 | 35 | 54% |
Single agent versus combination chemotherapy for metastatic breast cancer | 2009 | 33 | 44 | 61% |
Management of Metastatic Breast Cancer Monotherapy Options for Patients Resistant to Anthracyclines and Taxanes | 2010 | 20 | 40 | 65% |
Oral vinorelbine in metastatic breast cancer: A review of current clinical trial results | 2012 | 8 | 26 | 73% |
Gemcitabine in the management of metastatic breast cancer: a systematic review | 2008 | 27 | 47 | 91% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | NO ALBERTA BREAST CANC PROGRAM | 14 | 100% | 0.4% | 7 |
2 | CANC THER Y DEV PROGRAM | 6 | 80% | 0.2% | 4 |
3 | BREAST ONCOL GRP | 3 | 57% | 0.2% | 4 |
4 | BREAST CANC BIOL UNIT | 3 | 60% | 0.2% | 3 |
5 | BREAST CANC MED SERV | 3 | 12% | 1.1% | 20 |
6 | BERLIN BREAST CANC GRP | 2 | 67% | 0.1% | 2 |
7 | INVEST DRUG BRANCH BREAST CANC | 2 | 67% | 0.1% | 2 |
8 | SURG ONCOL A | 2 | 40% | 0.2% | 4 |
9 | BAYLOR SAMMONS CANC | 2 | 16% | 0.5% | 10 |
10 | ST CHIARA HOSP | 1 | 38% | 0.2% | 3 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000198861 | HIGH DOSE CHEMOTHERAPY//DOSE INTENSITY//HIGH RISK BREAST CANCER |
2 | 0.0000168734 | NAB PACLITAXEL//CREMOPHOR EL//NEW MAT BIOL |
3 | 0.0000145756 | VINFLUNINE//VINCA ALKALOIDS//ONCOL PHARMACOKINET |
4 | 0.0000129690 | TSU 68//APATINIB//MUCOCUTANEOUS TOXICITIES |
5 | 0.0000114311 | NON COLORECTAL//STAGE IV BREAST CANCER//NON NEUROENDOCRINE |
6 | 0.0000093103 | PEGFILGRASTIM//FEBRILE NEUTROPENIA//FILGRASTIM |
7 | 0.0000089834 | TRASTUZUMAB//LAPATINIB//PERTUZUMAB |
8 | 0.0000085152 | INFLAMMATORY BREAST CANCER//NEOADJUVANT CHEMOTHERAPY//LOCALLY ADVANCED BREAST CANCER |
9 | 0.0000084718 | VINORELBINE//GEMCITABINE//ADVANCED NON SMALL CELL LUNG CANCER |
10 | 0.0000073938 | ORAL CHEMOTHERAPY//ORAL ANTICANCER AGENTS//ORAL ANTICANCER DRUGS |